1	The effects of oxygenation on acute vasodilator challenge in pulmonary arterial
2	hypertension
3	
4	Matthew D Rockstrom ¹ , Ying Jin ² , Ryan A Peterson ² , Peter Hountras ³ , David Badesch ³ ,
5	Sue Gu ³ , Bryan Park ³ , John Messenger ⁴ , Lindsay M. Forbes ³ , William K. Cornwell III ⁴ ,
6	Todd M Bull ³
7	1) Department of Medicine, University of Colorado Anschutz Medical Campus,
8	Aurora, CO, United States
9	2) Department of Biostatistics & Informatics, Colorado School of Public Health,
10	University of Colorado Anschutz Medical Campus, Aurora, CO, United States
11	3) Department of Medicine, Division of Pulmonary Sciences and Critical Care
12	Medicine, Pulmonary Vascular Center, University of Colorado Anschutz Medical
13	Campus, Aurora, CO, United States
14	4) Department of Medicine, Division of Cardiology, University of Colorado Anschutz
15	Medical Campus, Aurora, CO, United States
16	Corresponding author:
17	Matthew Rockstrom
18	matthew.rockstrom@cuanschutz.edu
19	(509) 378-1906
20	Running head: Supplemental oxygenation and acute vasodilator challenge
21	Conflicts of Interest: None
22	
23	

24 Background:

Identification of long-term calcium channel blocker (CCB) responders with acute
vasodilator challenge is critical in the evaluation of patients with pulmonary arterial
hypertension. Currently there is no standardized approach for use of supplemental
oxygen during acute vasodilator challenge.

29 Methods:

30 Retrospective analysis of patients identified as acute vasoresponders, treated with

31 CCBs. All patients had hemodynamic measurements in three phases: 1) at baseline; 2)

32 with 100% fractional inspired oxygen; and 3) with 100% fractional inspired oxygen plus

inhaled nitric oxide (iNO). Patients were divided into two cohorts. Those meeting the

34 definition of acute vasoresponsiveness from phase 2 to phase 3 were labeled "iNO

35 Responders." Those who did not reach the threshold of acute vasoresponsiveness from

36 phase 2 to phase 3 but did meet the definition from phase 1 to phase 3 were labeled

37 "Oxygen Responders." Survival, hospitalization for decompensated right heart failure,

duration of CCB monotherapy, and functional data were collected.

39 Results:

40 iNO Responders, when compared to Oxygen Responders, had superior survival (100%

41 vs 50.1% 5-year survival, respectively), fewer hospitalizations for acute decompensated

right heart failure (0% vs 30.4% at 1 year, respectively), longer duration of CCB

43 monotherapy (80% versus 52% at 1 year, respectively), and superior six-minute walk

44 distance.

45 **Conclusion:**

- 46 Current guidelines for acute vasodilator testing do not standardize oxygen
- 47 coadministration with iNO. This study demonstrates that adjusting for the effects of
- 48 supplemental oxygen before assessing for acute vasoresponsiveness identifies a cohort
- 49 with superior functional status, tolerance of CCB monotherapy, and survival while on
- 50 long-term CCB therapy.

51 Pulmonary arterial hypertension (PAH) is a progressive disease of the small pulmonary 52 arteries characterized by increased pulmonary vascular resistance and eventual right 53 heart failure (1). Despite advancements in treatment, PAH is a life-limiting and often 54 terminal disease (2, 3). A subset of 5 – 10% of PAH patients demonstrate excellent 55 response to long-term calcium channel blockers (CCB) therapy (4). Recognition of long-56 term CCB responders is essential for selection of appropriate therapy and 57 prognostication as these patients have less severe functional impairments, improved hemodynamics, and significantly prolonged life span on CCB monotherapy (5, 6). 58 59 However, in unresponsive patients, CCB use is contraindicated and can cause 60 hemodynamic decompensation and increased mortality (6), making correct identification 61 of this population imperative. 62 Long-term CCB responders are identified by acute vasodilator challenge during right 63

64 heart catheterization (RHC) as part of the initial workup of PAH (7). Identification of 65 acute vasoresponders requires a reduction in mean pulmonary arterial pressure (mPAP) of \geq 10 mmHg reaching an absolute mPAP \leq 40 mmHg without a decrease in 66 67 cardiac output (CO) in response to an acute vasodilatory agent (6, 8). Inhaled nitric oxide (iNO) is an endogenous vasodilator produced by vascular endothelial cells and is 68 69 frequently used to assess acute vasoreactivity in PAH (9, 10). iNO can be delivered at 70 variable concentrations and is often co-administered with supplemental oxygen, 71 however there is significant variability in the use of supplemental oxygen during acute vasodilator challenge, ranging from maintenance of fractional inspired oxygen (FiO2) of 72 73 21% to use of 100% FiO2 administered with iNO (11-15). The effects of supplemental

74	oxygen are not inert, as alveolar hypoxia has long been understood to induce
75	pulmonary vasoconstriction and subsequent elevation in mPAP (16-18) and increased
76	alveolar oxygen tension reduces mPAP (19, 20) and pulmonary vascular resistance
77	(PVR) (21) in PAH patients.
78	
79	In this study, we evaluated the long-term tolerance of CCBs amongst two cohorts –
80	"iNO Responders," who meet the definition of acute vasoresponsiveness only after first
81	adjusting for the effects of supplemental oxygen, and "Oxygen Responders," who meet
82	the definition of acute vasoresponsiveness without adjusting for the vasodilatory effects
83	of oxygen. For each cohort, we follow tolerance of CCB monotherapy, mortality,
84	hospitalization for decompensated right heart failure, and functional status following the
85	initiation of CCB.
86	
87	Materials and Methods:
88	Study group
89	We retrospectively evaluated medical records of all patients, aged 18 or older, referred
90	to a large regional tertiary pulmonary hypertension care center (PHCC) for management
91	of their PAH from January 2010 to October 2021. The study was approved by the
92	Colorado Multiple Institutional Review Board (COMIRB Protocol #: 07-0953).
93	
94	PAH was defined by an mPAP \geq 25 mmHg with a pulmonary capillary wedge pressure
95	(PCWP) of < 15 mmHg and pulmonary vascular resistance (PVR) > 3 Woods units in
96	the absence of chronic thromboembolic pulmonary hypertension or significant chronic

97 respiratory disease (22). All PAH patients were evaluated and patients were identified 98 as vasoresponders if they 1) met the definition of acute vasoresponsiveness, with a 99 reduction in mPAP \geq 10 mmHg and a final mPAP \leq 40 mmHg (23); 2) were initially 100 treated with CCB monotherapy for their PAH; and 3) acute vasodilator challenge included a dedicated measurement of mPAP during an "oxygen phase" at 100% FiO₂, in 101 102 addition to hemodynamic measurements at baseline and "vasodilator phase" with 100% 103 FiO₂ and 40ppm iNO. In accordance with the American College of Chest Physicians 104 recommendations (24) for evaluation of acute vasoreactivity in pulmonary hypertension, 105 all World Health Organization (WHO) Group I patients (25) were eligible for enrollment 106 including: idiopathic PAH (iPAH), familial PAH (FPAH) and PAH associated with 107 connective tissue disease, portopulmonary hypertension, toxins, congenital heart disease, and HIV. We also performed a subgroup analysis of patients diagnosed with 108 iPAH, FPAH, and toxin-mediated PAH, in line with the 6th World Symposium on 109 110 Pulmonary Hypertension (WSPH) and European Society of Cardiology and European 111 Respiratory Sociate (ECS/ERS) recommendations (26, 27) for acute vasoreactivity 112 challenge. WHO class was determined by a clinician expert in the treatment of 113 pulmonary vascular disease and re-adjudicated by two authors (MR, TB).

114

115 Right heart catheterization and acute vasodilator challenge

All right heart catheterizations were performed using standard technique as previously
described (13). Baseline hemodynamic measurements including right atrial pressure
(RAP), mPAP, PWCP, and CO were first recorded on ambient room air. If the patient
had chronic oxygen requirements, baseline measurements were recorded at their home

supplemental oxygen dose with a goal saturation of peripheral oxygen (SpO₂) of 9094%. mPAP was recorded during an intermediate "oxygen phase," using 100%
supplemental oxygen via non-rebreather face mask for 2 minutes. Finally, complete
hemodynamic measurements were repeated during a final "vasodilator phase,"
following administration of 40 ppm of iNO and 100% supplemental oxygen for 5
minutes.

126

127 Responder definitions, CCB administration, and monitoring

Patients were designated as "iNO Responders" if they met the definition of acute
vasoresponsiveness from the effects of iNO after first normalizing for the effects of
supplemental oxygen. If patients met the definition of acute vasoresponsiveness only
through a combination of the effects of oxygen and iNO, they were labeled "Oxygen
Responders" (*Figure 1*).

133

134 Selection and titration of a CCB agent was performed at the discretion of the treating 135 pulmonary hypertension provider. CCB monotherapy was discontinued if the patient did 136 not have favorable functional response: improvement to NYHA FC I or II, a lack of 137 improvement in 6MWD, or if they had evidence of worsening mPAP or right ventricular 138 function on transthoracic echocardiogram or RHC. NYHA functional status and 6MWD 139 were collected by chart review at baseline, 1-, and 3-year follow-up. Hospitalizations for 140 acute decompensated right heart failure within the first year of initiation of CCB were 141 observed. Additionally, time on CCB monotherapy and mortality from time of initiation of 142 CCB were collected.

143

144 Statistical analysis

145 For demographic variables, we presented summary statistics stratified by

146 vasoresponsive status alongside non-parametric statistical tests (Kruskal-Wallis tests

147 for continuous variables, Fisher's exact test for categorical variables). For time-to-event

148 outcomes, we presented stratified Kaplan-Meier estimates of event-free probabilities, as

149 well as *P* values from log-rank tests. We computed restricted means for each event time

150 for additional descriptive statistics as the median event time was not observed for all

151 outcomes. For the longitudinal outcome of 6MWD, we presented summary statistics and

152 visualizations of means and standard deviations stratified by vasoresponsive status.

153 Differences at each time were assessed using a linear mixed model with subject-level

154 random intercepts and fixed effects for time, vasoresponsive status, and their

interaction. Using the mixed model for 6MWD, group-level differences at each time were

156 tested using t-tests with the Kenward-Roger approximation for degrees of freedom,

157 while differences in NYHA classification were tested separately at each time point using

158 Fisher's Exact tests.

159

160 **Results:**

Two hundred sixty eight consecutive PAH patients were identified. Of these, 91 patients (30.3%) had iPAH, 3 (1.0%) had familial PAH, and 206 (68.7%) had associated PAH. A total of 33 acute vasoresponders were identified. Amongst these, 10 were "iNO Responders" and 23 were "Oxygen Responders". Average duration of follow up was 4.5 years. Basic demographic characteristics and rates of comorbid systemic hypertension,

type 2 diabetes mellitus, and smoking history were similar between the two cohorts.

- 167 Eight iNO Responders and 16 Oxygen Responders had chronic oxygen requirements
- 168 (80% versus 69.6%, respectively, *P* = 0.037). Amongst iNO Responders, 7 (70.0%) had

iPAH, 2 (20.0%) had CTD-associated PAH, and 1 (10.0%) had FPAH. Amongst Oxygen

- 170 Responders, 6 (26.1%) had iPAH and 17 (73.9%) had associated PAH, including 8
- 171 (34.8%) with CTD, 4 (17.4%) toxin associated, 3 (13.0%) with congenital heart disease.
- 172 2 (8.7%) with portopulmonary disease (*Table 1*).
- 173

174 Hemodynamics:

- 175 Baseline hemodynamic measurements between iNO Responders and Oxygen
- 176 Responders revealed similar baseline RAP, mPAP, PCWP, and PVR. Amongst iNO
- 177 Responders, there was lower mean baseline CO than Oxygen Responders (4.0 +/- 1.1
- versus 5.6 +/- 2.1 L/min, respectively, *P* = 0.010). Oxygen Responders trended towards
- 179 lower mPAP than iNO Responders during oxygen phase (35.8 versus 44.3 mmHg,
- respectively, *P* = 0.057) and both iNO Responders and Oxygen Responders had similar
- 181 mPAP during vasodilator phase (30.0 +/- 7.7 versus 29.8 +/- 7.4 mmHg, P = 0.89).
- 182 (*Table 2*). Oxygen Responders had a greater reduction in mPAP from baseline to
- 183 oxygen phase than iNO Responders (8.0 versus 4.3 mmHg, respectively, P = 0.021)
- and iNO Responders' reduction in mPAP was similar to that seen in the overall cohort of
- 185 268 PAH patients (3.9 mmHg). iNO Responders had a greater reduction in mPAP from
- 186 oxygen phase to vasodilator phase than Oxygen Responders (14.4 versus 6.0 mmHg,
- 187 respectively, *P* < 0.001) (*Figure 2*).
- 188

189 Survival, hospital free survival, CCB monotherapy:

190	iNO Responders had superior survival and hospital-free survival relative to Oxygen
191	Responders (Figure 3). There were no deaths within 10 years of initiation of CCB
192	amongst iNO Responders. Amongst Oxygen Responders, survival was 87.0% at one
193	year, 71.6% at 3 years, and 50.1% at 5 years from initiation of CCB. Additionally, there
194	were no hospitalizations for acute decompensated right heart failure within a year of
195	initiation of CCB amongst iNO Responders as compared to 7 (30.4%) amongst Oxygen
196	Responders. iNO Responders had greater tolerance of CCB monotherapy compared to
197	Oxygen Responders (Figure 4). At one year follow up, 80% of iNO Responders were
198	still on monotherapy as compared to 52% of Oxygen Responders. Restricted 10-year
199	mean time of CCB monotherapy was 6.0 years versus 2.8 years in iNO Responders
200	and Oxygen Responders, respectively (log rank $P = 0.0085$).
201	

201

A subgroup analysis of patients with iPAH, FPAH, and toxin-mediated PAH

203 demonstrated that iNO Responders had longer survival time (*P* = 0.009) and hospital-

free survival time (*P* = 0.013) than Oxygen Responders (*Figure 5*). Additionally, iNO

205 Responders had longer time on monotherapy than Oxygen responders (7.4 versus 1.5

206 years, respectively, P = 0.085).

207

208 Functional status:

The 6MWD of iNO Responders and Oxygen Responders were 423 versus 352 meters at baseline (P = 0.45), 409 versus 292 meters at 1-year (P = 0.21), and 454 versus 224

211 meters at 3-years, respectively (P = 0.017) (*Figure 6*). iNO Responders trended towards

superior functional class at 1- and 3-year follow up, although this did not reach the
threshold for statistical significance (*Table 3*).

214

215 Discussion:

216 Accurate identification of long-term CCB responders is a critical step in the evaluation of 217 patients with PAH (7, 28). Correct identification with acute vasodilator challenge selects 218 for patients with improved functional status and decreased mortality (4-6). Incorrect 219 identification can lead to deleterious effects from CCB therapy including decreased 220 cardiac output, decreased systemic mean arterial pressure, decompensated functional 221 status, and increased mortality (6). Due to the potential hemodynamic instability caused 222 by acute vasoresponder testing with short-acting CCBs (29-31), other agents are 223 preferentially used. iNO is a safe, well-tolerated, and frequently utilized vasodilator 224 agent in acute vasodilator challenge (10). iNO is delivered at variable concentrations 225 and is often co-administered with oxygen, although there is significant variability in how 226 oxygen is utilized (11-15). At present, there is no standardized protocol for the utilization 227 of oxygen or the interpretation of the effects of oxygen on changes in mPAP during 228 acute vasodilator challenge. In this study, we demonstrate that defining acute 229 vasoresponsiveness after first adjusting for the effects of oxygenation identifies a group 230 which has excellent long-term responsiveness to CCBs. Conversely, treating patients 231 who primarily respond to oxygen, without a significant additional response to iNO, with 232 calcium channel blockers may result in harm and delay appropriate treatment.

233

234 During acute vasodilator challenge, both iNO Responders and Oxygen Responders had 235 a similar overall change in mPAP from baseline to vasodilator phase. However, when 236 the effects of oxygen are isolated, two distinct patterns of response emerge. Amongst 237 Oxygen Responders, over half (56.1%) of their overall decrease in mPAP occurred due 238 to the effects of oxygenation alone. Conversely, iNO Responders had 77% of their 239 overall reduction in mPAP from oxygen phase to vasodilator phase. The reduction in 240 mPAP from oxygen phase to vasodilator phase was nearly 2.5 times greater in iNO Responders than in Oxygen Responders (mean decrease in mPAP of 14.4 versus 6 241 242 mmHg, respectively). The relationship between alveolar oxygen tension and pulmonary 243 arterial vascular tone is well described (16-18) and hyperoxia has been shown to 244 modulate mPAP (19, 20) and PVR (21) in PAH patients. Our overall cohort of 268 PAH 245 patients had a reduction in mPAP of 3.8 mmHg, similar reduction in mPAP to other trials 246 (19, 20). Without adjusting for the known vasodilatory effects oxygen, it is possible to 247 incorrectly attribute vasoresponsiveness to iNO.

248

249 There was a particularly striking difference in mortality between the two cohorts. The 250 iNO Responder cohort had no deaths in a 10-year period. Amongst Oxygen 251 Responders, the mortality rate at 5 years exceeded 50%. Six of the 8 deaths that 252 occurred in this cohort were from progressive right heart failure and all patients were on 253 a multi-drug regimen for management of their PAH prior to their death. Subgroup 254 analyses restricted to patients recommended to undergo acute vasoreactivity testing by 255 the WSPH and ECS/ERS guidelines (26, 27) – iPAH, FPAH, and toxin-mediated PAH – 256 yielded similar results. In this WSPH and ECS/ERS cohort, no deaths were observed in

257 the iNO Responder group and the mortality amongst the Oxygen Responders was 258 100% at 5 years. This robust survival benefit observed amongst iNO Responders is in 259 keeping with the excellent long-term prognosis described in long-term CCB responders 260 (4, 6, 8). The accelerated mortality seen amongst Oxygen Responders is also 261 consistent with prior cohorts of non-CCB responders who received initially CCB therapy 262 (6). The 10-year restricted mean duration of CCB monotherapy was 6.0 in iNO 263 Responders versus 2.8 in Oxygen Responders and nearly half of Oxygen Responders 264 had failed CCB monotherapy after one year. Subgroup analysis of iPAH, FPAH, and 265 toxin-mediated PAH demonstrated similar monotherapy tolerance for iNO Responders 266 and Oxygen Responders (7.4 versus 1.5 years, respectively, P = 0.085), Additionally, 7 267 of the 23 (30.4%) Oxygen Responders had acute decompensated right heart failure 268 within a year of initiation of CCB therapy while no iNO Responders had decompensated 269 right heart failure within a year of CCB initiation. 270

Overall, iNO Responders and Oxygen Responders had similar baseline functional
characteristics. However, at 1- and 3-year follow up, iNO Responders had an overall
increase in their 6MWD while Oxygen Responders had a progressive decline in over
this time period. At baseline, there were no significant differences in NYHA functional
status. During follow up at 1 and 3 years, the proportion of iNO Responders who were
NYHA I or II versus NYHA III or IV remained higher than in Oxygen Responders, though
this never reached the threshold of statistical significance.

278

279 It is interesting to note that a significant difference exists between the proportion of 280 patients with idiopathic and associated PAH amongst the two cohorts. However, there 281 were no significant differences in survival or tolerance of monotherapy amongst patients 282 with iPAH versus associated PAH in the Oxygen Responder cohort. Additionally, if both 283 iNO Responders and Oxygen Responders are considered, there is a higher-than-284 expected rate of vasoresponsiveness amongst both associated PAH patients (9.2% 285 vasoresponsive) and iPAH patients (14.3% vasoresponsive). If we consider iNO 286 Responders alone, the rates are more aligned with expected values, with 1.0% of all 287 associated PAH patients and 7.7% of all iPAH patients meeting the definition of acute 288 vasoresponders. This demonstrates that, without correcting for oxygen, we likely 289 decrease the specificity of acute vasodilator challenge and over diagnose acute 290 vasoresponsiveness.

291

292 It is also notable that the study is from a pulmonary hypertension center which is located 293 at an altitude of 5,280 feet above sea level. The phenomenon of reduced mPAP in PAH 294 patients following administration of supplemental oxygen has been described at other 295 altitudes. Both the average reduction in mPAP (~ 4 mmHg) and distribution (upper 296 quartile of responders with \geq 6 mmHg of mPAP reduction) in our overall cohort of 268 PAH patients is consistent with other studies of PAH patients exposed to 100% FiO2 at 297 298 lower altitudes (19, 20). This suggests that the response to oxygen in our cohort in 299 neither unique nor disproportionate in magnitude or distribution to that of PAH patients 300 at other altitudes. Additionally, our protocol of collecting baseline hemodynamic 301 measurements at patients' home oxygen requirement with SpO_2 between 90%-94%

302 should ameliorate the effects of altitude-related hypoxemia. It is also interesting to note 303 that the rates of chronic oxygen requirement were higher amongst the iNO Responders 304 than the Oxygen Responders, suggestive that preexisting chronic oxygen requirement 305 is not a driving factor in oxygen responsiveness. During the course of this study, a new 306 definition was proposed for pulmonary hypertension, using mPAP \geq 20 mmHg as the 307 threshold for diagnosis rather than the traditional definition of mPAP \geq 25 mmHg (8). It 308 remains unclear how inclusion of patients with mPAP from 20 – 24 mmHg will affect the 309 incidence or prognosis of long-term CCB response. However, a standardized approach 310 to the workup of PAH patients will remain imperative.


311

312 Interpretation:


313 The results of our study suggest that consideration of effects of oxygen during acute 314 vasodilator challenge is critical for proper identification of long-term CCB responders. 315 Stepwise evaluation of the effects of supplemental oxygen and iNO revealed a subset of 316 patients with an exaggerated response to supplemental oxygenation. Failure to correct 317 for the effects of oxygen on mPAP in the interpretation of acute vasodilator challenge 318 with iNO selects for a patient population with inferior long-term response to CCBs, 319 higher rates of decompensated right heart failure, and decreased survival. Those 320 patients who demonstrate vasoresponsiveness to iNO independent from the effects 321 oxygen have excellent long-term response to CCB monotherapy, superior functional 322 status, and increased survival. These findings should be validated across a variety of 323 settings. Ultimately, a standardized approach for the use of supplemental oxygen during 324 acute vasodilator challenge with iNO is necessary.

- 325 <u>Guarantor statement:</u>
- 326 Matthew Rockstrom, MD is the guarantor of all content of the manuscript including data
- 327 and analysis.
- 328
- 329 <u>Author contributions:</u>
- 330 All listed authors met ICMJE qualifications for authorship.
- 331
- 332 Financial/Nonfinancial disclosures:
- 333 We have no financial disclosures or conflicts of interest to report

334 Tables and Figures



- 336 Fig 1: Definitions of iNO and Oxygen Responders. Mean pulmonary arterial pressure (mPAP) was
- 337 measured at baseline (ambient room air or patient's chronic home oxygen requirement, if applicable),
- 338 after 2 min at 100% fractional inspired oxygen ("Oxygen Phase"), and after 5 min at 100% $FiO_2 + 40$ ppm
- inhaled nitric oxide ("Vasodilator Phase"). Both iNO and Oxygen responders had a reduction of ≥ 10
- 340 mmHg from baseline to Vasodilator Phase with a final mPAP \leq 40 mmHg. "iNO Responders" had a \geq 10
- 341 *mmHg* reduction in mPAP from Oxygen Phase to Vasodilator Phase. "Oxygen Responders" had a < 10
- 342 *mmHg reduction in mPAP from Oxygen Phase to Vasodilator Phase.*




345 Fig 2. Mean pulmonary arterial pressure (mPAP) for iNO Responders (shown in red) and Oxygen

346 Responders (shown in blue) measured at baseline, following administration of 100% FiO₂ (indicated as

347 "O2"), and following administration of 100% FiO₂ with 40 ppm iNO (indicated as "iNO"). Ribbons represent

348 the average mPAP +/- 1 standard error, calculated separately from data at each time point




351

352 Fig 3. Kaplan-Meier curves for survival (above) and hospitalization-free survival (below) following initiation 353 of calcium channel blocker therapy for 33 patients, subdivided into iNO Responders (n = 10 at initiation, 354 shown in red) and Oxygen Responders (n = 23 at initiation, shown in blue). Dotted lines indicate mean 355 survival time and hospitalization-free survival time, respectively. Restricted mean 10-year survival time

356 amongst Oxygen Responders was 8.59 years and was 6.71 years for hospitalization-free survival. All

357 relationships were statistically significant.



358


359 Fig 4. Kaplan-Meier curve for calcium channel blocker monotherapy amongst 33 patients, subdivided into

360 *iNO* Responders (*n* = 10 at initiation) and Oxygen Responders (*n* = 23 at initiation). Dotted lines indicate

361 mean duration of monotherapy for both cohorts. Restricted mean 10-year duration of monotherapy for

362 *iNO Responders was 6.01 years and for Oxygen Responders was 2.76 years.*


Strata 🔶 iNO responders 🛨 Oxygen responders



365 366 Fig 5. Kaplan-Meier curves for survival (above) and hospitalization-free survival (below) following initiation of calcium channel blocker therapy for subgroup analysis of patients meeting recommendations for acute vasoresponsiveness screening per 6th World Symposium of Pulmonary Hypertension (WSPH) and 367 368 European Society of Cardiology/European Respiratory (ERC/ERS) guidelines. Dotted lines indicate mean 369 370 survival time and hospitalization-free survival time, respectively.

371

372



374

Fig 6. Average six-minute walk distance (6MWD) in meters at time of initiation of calcium channel blocker

376 (Baseline) as well as 1-year and 3-year follow up for iNO Responders and Oxygen Responders. Baseline,

377 1-year, and 3-year 6MWD for iNO Responders were 423 m, 409 m, 454 m, respectively and for Oxygen

378 Responders were 352 m, 292 m, and 224 m, respectively. Ribbons indicate the average 6MWD +/- 1

379 standard error, calculated separately from data at each time point.

381 Table 1: Baseline Clinical Characteristics and Calcium Channel Blocker Use of

382 Study Cohort

383

	iNO Responders (N=10)	Oxygen Responders (N=23)	Total (N=33)	<i>P</i> value
Baseline Characteristic	S			
Age at Index (SD)	57.6 (17.3)	52.9 (17.0)	54.3 (16.9)	0.505
Sex (%)	3 (30.0)	5 (21.7)	8 (24.2)	0.673
BMI (SD)	24.0 (4.3)	26.7 (7.1)	25.9 (6.5)	0.337
Comorbidities				
COPD (%)	2 (20.0)	2 (8.7)	4 (12.1)	0.567
Systemic HTN (%)	3 (30.0)	7 (30.4)	10 (30.3)	1.000
T2DM (%)	2 (20.0)	2 (8.7)	4 (12.1)	0.567
Ever smoker (%)	2 (20.0)	7 (30.4)	9 (27.3)	0.686
PAH Subtype				
Idiopathic (%)	7 (70.0)	6 (26.1)	13 (39.4)	0.026
Familial (%)	1 (10.0)	0 (0.0)	1 (3.0)	0.303
Associated (%)				1.000
CHD	0 (0.0)	2 (11.8)	2 (10.5)	
CTD	2 (100.0)	8 (47.1)	10 (52.6)	
Multi	0 (0.0)	1 (5.9)	1 (5.3)	
Other	0 (0.0)	1 (5.9)	1 (5.3)	
Portopulmonary	0 (0.0)	1 (5.9)	1 (5.3)	
Toxins	0 (0.0)	4 (23.5)	4 (21.1)	
ССВ				
Amlodipine (%)	6 (60.0)	20 (87.0)	26 (78.8)	0.161
Diltiazem (%)	4 (40.0)	3 (13.0)	7 (21.2)	0.161

384

385

386 BMI: body mass index (kg/m²), COPD: chronic obstructive pulmonary disease, HTN: hypertension, T2DM:

type 2 diabetes mellitus, PAH: pulmonary arterial hypertension, CTD: connective tissue disease, CCB:
 calcium channel blocker

Table 2: Hemodynamic Data for Study Cohort during Right Heart Catheterization 391

	iNO Responders (N=10)	Oxygen Responders (N=23)	P value
Baseline			
RAP, mmHg (SD)	5.10 (3.54)	5.78 (3.00)	0.568
mPAP, mmHg (SD)	48.70 (13.62)	43.83 (7.82)	0.398
PCWP, mmHg (SD)	7.90 (3.67)	9.52 (3.70)	0.243
CO,TD L/min (SD)	3.97 (1.11)	5.61 (2.15)	0.010
CO,Fick L/min (SD)	4.04 (1.06)	4.91 (1.15)	0.051
PVR, WU (SD)	11.03 (5.85)	8.14 (3.47)	0.177
Oxygen Phase			
mPAP, mmHg (SD)	44.40 (11.72)	35.83 (7.72)	0.057
Vasodilator Phase			
RAP, mmHg (SD)	4.60 (2.91)	4.83 (3.20)	0.735
mPAP, mmHg (SD)	30.00 (7.73)	29.83 (7.43)	0.890
PCWP, mmHg (SD)	8.00 (3.86)	10.61 (4.12)	0.051
CO,TD L/min (SD)	4.17 (1.22)	5.10 (1.77)	0.183
PVR, WU (SD)	5.55 (2.49)	3.89 (2.07)	0.044

392 393

393

394 All figures listed with standard deviations in parentheses; RAP: right atrial pressure; mPAP: mean

pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; CO: cardiac output; TD:
 thermodilution; PVR: pulmonary vascular resistance; WU: Woods Units

397 "Oxygen Phase" with hemodynamic measurements taken after 100% supplemental oxygen for 2 minutes;

398 "Vasodilator Phase" with hemodynamic measurements take after 100% supplemental oxygen + 40 ppm

iNO for 5 min

Table 3: New York Heart Association Functional Class for Studied Cohort at Baseline, 1-year, and 3-year Follow Up

403

	iNO Responders (N=10)	Oxygen Responders (N=23)	P value
Baseline			0.678
Ι	1 (11.1%)	3 (16.7%)	
II	7 (77.8%)	9 (50.0%)	
III	1 (11.1%)	5 (27.8%)	
IV	0 (0.0%)	1 (5.6%)	
Year 1			1.000
I	2 (40.0%)	1 (20.0%)	
II	2 (40.0%)	2 (40.0%)	
111	1 (20.0%)	2 (40.0%)	
Year 3			0.679
Ι	2 (40.0%)	0 (0.0%)	
П	2 (40.0%)	1 (33.3%)	
111	1 (20.0%)	2 (66.7%)	

404

405 New York Heart Association classes I – IV (indicated as I, II, III, and IV) recorded at time of right heart

406 catheterization and again at one-year and three-year follow up

407 Rubin LJ. Primary pulmonary hypertension. Chest. 1993;104(1):236-50. 1. 408 2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-409 term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL 410 Registry, Chest. 2012:142(2):448-56. 411 Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality 3. 412 in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2). 413 414 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on 4. 415 survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81. 416 Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary 5. 417 pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987;76(1):135-41. 418 419 Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response 6. 420 to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 421 2005;111(23):3105-11. 422 7. Hassoun PM. Pulmonary Arterial Hypertension. N Engl J Med. 2021;385(25):2361-76. 423 Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. 8. 424 Haemodynamic definitions and updated clinical classification of pulmonary hypertension. The 425 European respiratory journal. 2019;53(1):1801913. 426 Hill NS, Preston IR, Roberts KE. Inhaled Therapies for Pulmonary Hypertension. Respir 9. 427 Care. 2015;60(6):794-802; discussion -5. 428 Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric 10. 429 oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in 430 primary pulmonary hypertension. Eur Respir J. 1998;12(2):265-70. 431 11. Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary 432 vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert 433 consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. 434 The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. 435 Heart. 2016;102 Suppl 2:ii23-9. 436 Frantz RP, Leopold JA, Hassoun PM, Hemnes AR, Horn EM, Mathai SC, et al. Acute 12. 437 vasoreactivity testing during right heart catheterization in chronic thromboembolic pulmonary 438 hypertension: Results from the pulmonary vascular disease phenomics study. Pulm Circ. 439 2023;13(1):e12181. 440 Hunt JM, Risbano MG, Messenger JC, Carroll J, Badesch D, Lowes BD, et al. Timed 13. 441 response to inhaled nitric oxide in pulmonary hypertension. Pulm Circ. 2014;4(1):103-9. 442 14. Kumar S, Memon D, Raj M, Sen AC, Jayasankar JP, Leeladharan SP, et al. Comparison of 443 intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary 444 arterial hypertension. Pulm Circ. 2022;12(4):e12180. 445 Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide 15. 446 as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study 447 and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151(2 Pt 1):384-9. 448 Bradford JR, Dean HP. The Pulmonary Circulation. J Physiol. 1894;16(1-2):34-158 25. 16.

449 17. Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A, Parlow LRG, Mewburn JD, et al. Hypoxic

450 Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. Chest.

451 2017;151(1):181-92.

452 18. Euler U, Liljestrand G. Observations on the Pulmonary Arterial Blood Pressure in the Cat.
453 Acta Physiologica Scandinavica. 1946;12(4):301-20.

454 19. Carta AF, Lichtblau M, Berlier C, Saxer S, Schneider SR, Schwarz EI, et al. The Impact of
455 Breathing Hypoxic Gas and Oxygen on Pulmonary Hemodynamics in Patients With Pulmonary
456 Hypertension. Front Med (Lausanne). 2022;9:791423.

Groth A, Saxer S, Bader PR, Lichtblau M, Furian M, Schneider SR, et al. Acute
hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial
and chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2018;270:262-7.

460 21. Leuchte HH, Baezner CJ, Baumgartner RA, Mernitz P, Neurohr C, Behr J. Acute 461 hemodynamic responses to supplemental oxygen and their prognostic implications in 462 pulmonary byportoncion. Pospiration, 2012;85(5):400.7

462 pulmonary hypertension. Respiration. 2013;85(5):400-7.

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al.
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25
Suppl):D34-41.

466 23. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 467 2009 expert consensus document on pulmonary hypertension: a report of the American College

468 of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart

469 Association: developed in collaboration with the American College of Chest Physicians,

470 American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation.471 2009;119(16):2250-94.

472 24. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for
473 Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel
474 Report. Chest. 2019;155(3):565-86.

Prins KW, Thenappan T. World Health Organization Group I Pulmonary Hypertension:
Epidemiology and Pathophysiology. Cardiol Clin. 2016;34(3):363-74.

477 26. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS

478 Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for

the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology

480 (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European

481 Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung
482 Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-75.

483 27. Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World 484 Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53(1).

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al.
Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur
Respir J. 2019;53(1).

488 29. Aromatorio GJ, Uretsky BF, Reddy PS. Hypotension and sinus arrest with nifedipine in 489 pulmonary hypertension. Chest. 1985;87(2):265-7.

490 30. Farber HW, Karlinsky JB, Faling LJ. Fatal outcome following nifedipine for pulmonary491 hypertension. Chest. 1983;83(4):708-9.

492 31. Partanen J, Nieminen MS, Luomanmaki K. Death in a patient with primary pulmonary

493 hypertension after 20 mg of nifedipine. N Engl J Med. 1993;329(11):812; author reply -3.